Azibiot NEO 40 mg/ml prášok na perorálnu suspenziu Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

azibiot neo 40 mg/ml prášok na perorálnu suspenziu

krka, d.d., novo mesto, slovinsko - azitromycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Azibiot NEO 20 mg/ml prášok na perorálnu suspenziu Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

azibiot neo 20 mg/ml prášok na perorálnu suspenziu

krka, d.d., novo mesto, slovinsko - azitromycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Ilumetri Európska únia - slovenčina - EMA (European Medicines Agency)

ilumetri

almirall s.a - tildrakizumab - svrab - imunosupresívami, interleukín inhibítory, - ilumetri je indikovaný na liečbu dospelých so stredne ťažkým až ťažkým lupienky, ktorí sa uchádzajú o systémová terapia.

Skyrizi Európska únia - slovenčina - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresíva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Byfavo Európska únia - slovenčina - EMA (European Medicines Agency)

byfavo

paion deutschland gmbh - remimazolam besilate - vedomie sedácie - psycholeptika - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Wegovy Európska únia - slovenčina - EMA (European Medicines Agency)

wegovy

novo nordisk a/s - semaglutide - obesity; overweight - prípravky proti obezite, okrem diétne výrobky - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.